Low-Carbon Albuterol Inhaler for Asthma Clinical Data

Low-Carbon Albuterol Inhaler for Asthma Clinical Data

October 27, 2025 Jennifer Chen Health

Here’s a breakdown of the key facts ​from the provided text:

* Carbon Footprint Reduction: Switching from albuterol HFA-134a MDIs to albuterol HFA-152a MDIs can significantly reduce the ⁣carbon⁢ footprint – approximately a 92% reduction.
* CO2e Emissions:

​‍ * albuterol HFA-134a ‍MDI: 0.76 kg CO2e per device
* albuterol​ HFA-152a MDI: (Implied to be significantly lower due to the 92% reduction)
⁣* albuterol DPI: 0.76 kg CO2e per device
* Key Driver of Reduction: The reduction ⁤in carbon footprint is primarily due to ​changes in how patients use the inhaler (the “patient use phase”).
* Patient Preference: Many patients with asthma and COPD prefer MDIs (specifically albuterol MDIs) over alternatives like ‍dry powder inhalers (DPIs) or soft mist inhalers.
* Importance of the Finding: This new propellant (HFA-152a)⁤ allows patients to continue using their⁢ preferred inhaler type while helping healthcare systems meet climate goals.
* Source: The information comes from a news release by GSK (dated October⁣ 22, 2025)‌ regarding ‌positive Phase III trial data for a low-carbon version of Ventolin⁣ (salbutamol) MDI.